Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
Log in

HSCO Clinical Education Series

6-Part Virtual Series

August 21, 2020 The Evolution of Systemic Therapy for Advanced Urothelial Cancer 
September 11, 2020 Clinical Updates in Breast Cancer Treatment
September 25, 2020 Clinical Updates in Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia
October 2, 2020 An Update on Hepatobiliary and Pancreatic Cancer
October 16, 2020 Evaluation and Management Code Changes for 2021
October 30, 2020 State and Federal Policy Updates - Not eligible for CE

Webinars

8:00 - 9:00 AM Hawaii Time (2:00 - 3:00 PM Eastern Daylight Time)

These educational activities are jointly provided by AXIS Medical Education and Hawaii Society of Clinical Oncology (HSCO).

Target Audience

This activity is intended for all members of the multidisciplinary cancer care team including physicians, nurses, nurse practitioners, pharmacists, physician assistants, managers, billers/coders, and social workers.       

8.21.20 Overview

Discover the use of biomarkers to guide treatment decisions in localized bladder cancer, and first line and systemic therapy for the treatment of metastatic urothelial cancer.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Describe the latest recommendations for diagnosing, treating and monitoring patients with kidney cancer and bladder cancer. 
  2. Evaluate tools and resources for managing kidney cancer and bladder cancer that can be used to deliver effective care and improve the patient experience. 
  3. Identify emerging trends and strategies to improve symptom management and survivorship care. 
  4. Apply new knowledge to improve the delivery of effective and appropriate care to patients with kidney cancer and bladder cancer.      

9.11.20 Overview

Explore clinical updates in adjuvant and neoadjuvant therapies for breast cancer of all subtypes, and new treatment strategies for breast cancer brain metastases with an emphasis on HER2+ breast cancer.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. List the current standard care systemic therapies for early stage and metastatic breast cancer across all subtypes.
  2. Identify biomarkers predictive of response and resistance to common breast cancer systemic therapies.
  3. Summarize cutting-edge research directions for all stages of breast cancer. 

9.25.20 Overview

Hear the latest updates on novel therapies for indolent non-Hodgkin lymphoma, treatment sequencing for aggressive non-Hodgkin lymphoma, and treatment options for chronic lymphocytic leukemia.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Describe the latest recommendations for diagnosing, treating, and monitoring non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.  
  2. Identify emerging strategies for improving the quality of symptom management and survivorship care for patients with non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.  
  3. Evaluate tools and resources for managing non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia that can be used to achieve effective care and improve the patient experience.  
  4. Apply new knowledge to improve the delivery of effective and appropriate care to patients with non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.   

10.02.20 Overview

Learn about the recent developments and current treatment algorithms for hepatocellular carcinoma, and understand the recent advances in pancreatic cancer and systemic therapy for biliary tract cancers.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Describe the latest recommendations for diagnosing, treating, and monitoring hepatobiliary, pancreatic, and gastroesophageal cancers.   
  2. Identify emerging strategies for improving the quality of symptom management and survivorship care for patients with hepatobiliary, pancreatic, and gastroesophageal cancers.  
  3. Evaluate tools and resources for managing hepatobiliary, pancreatic, and gastroesophageal cancers that can be used to achieve effective care and improve the patient experience.   
  4. Apply new knowledge to improve the delivery of effective and appropriate care to patients with hepatobiliary, pancreatic, and gastroesophageal cancers. 

10.16.20 Overview

On January 1, 2021, big transformations to the office and outpatient evaluation and management (E&M) services (CPT® codes 99202-99215) will take place. Come away with essential information and applicable strategies to strengthen your cancer program’s operations and prepare for these changes.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Summarize the Evaluation and Management code changes for 2021. 
  2. Identify strategies for selecting the appropriate E/M codes based on the new criteria.
  3. Identify steps to prepare a practice for the transition. 

Faculty

8.21.20

Elizabeth Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center, Temple University

(Moderator) Ian Okazaki, MD  

Board Member, HSCO
Medical Oncologist
Straub Clinic and Hospital   

9.11.20

Carey Anders, MD 
Medical Oncologist 
Duke Cancer Center 

9.25.20

Julie Vose, MD, MBA 
Professor, Internal Medicine 
Division of Oncology & Hematology 
University of Nebraska Medical Center, College of Medicine

10.02.20

William Harris, MD 
Associate Professor, Division of Oncology 
University of Washington School of Medicine; Seattle Cancer Care Alliance

10.16.20

Allison M. Hirschorn 
Senior Coding and Reimbursement Specialist, Clinical Affairs 

American Society of Clinical Oncology 

10.30.20

Blake Oshiro
Executive Vice President, Public Policy
Capitol Consultants of Hawaii

Teri Bedard, RT(R)(T), CPC
Executive Director, Client & Corporate Resources
Revenue Cycle Coding Strategies

Christian G. Downs, JD, MHA
Executive Director
Association of Community Cancer Centers


ACCREDITED CONTINUING EDUCATION

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, these activities have been planned and implemented by AXIS Medical Education and Hawaii Society of Clinical Oncology (HSCO).  AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

IPCE Logo

These activities were planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit each for learning and change.

 

Credit Designation for Physicians
AXIS Medical Education designates these live activities for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ each. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation for Nursing
AXIS Medical Education designates these continuing nursing education activities for 1.0 contact hour each. 

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.  

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: 

 

Name of Faculty or Presenter/Planner Reported Financial Relationship
   

Carey Anders, MD

Research Funding: G1-Therapeutics, Lilly, Merck, Nektar, PUMA, Seattle Genetics, Tesaro

Consulting: AstraZeneca, Eisai, Genentech, IPSEN, Novartis, Seattle Genetics

Honorarium: UpToDate and Jones & Bartlett

William Harris, MD

Advisor: Eisai, Zymeworks

Contracted Research: Agios, Basilea, Bayer, BTG, BMS, Exelixis, Merck, Medimmune

Allison M. Hirschorn 

Nothing to disclose

Ian Okazaki, MD

Nothing to disclose

Elizabeth Plimack, MD, MS

Research Grant: Astellas, BMS, Genentech, Merck

Scientific Advisory: AstraZeneca, Genentech, Infinity Pharma, Merck, Pfizer, Seattle Genetics

Sponsored and Non-Sponsored CME Programs: ASCO GU, Clinical Care Options Fox Chase Cancer Center, Mt. Sinai Icahn School of Medicine, Medscape, NCCN, OncLive, PER, Research to Practice, Spire Learning, University of Pennsylvania, Thomas Jefferson Kimmel Cancer Center

Julie Vose, MD, MBA

Advisor: AbbVie, Epizyme, Legend Pharmaceuticals, Vaniam Group, Janssen/Pharmacyclics, Kite Pharma, Acerta/AstraZeneca, Verastem, Miltenyi Biotec Inc., Loxo Oncology, Allogene, Wugene, Celgene

Research Grant: Acerta/AstraZeneca, Celgene, Incyte Corp., Kite Pharma, Novartis, Seattle Genetics, Inc. 

 

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

 

Name of Planner/Manager/Reviewer Reported Financial Relationship
   

Michael Carney

Nothing to disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Christy Levine

Nothing to disclose

Charles Miller, MD

Nothing to disclose

Dee Morgillo, MEd., MT (ASCP) CHCP

Nothing to disclose

Ryon Nakasome, MD

Nothing to disclose

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

  • Attend/participate in the educational activity and review all course materials.
  • Complete the CE Declaration form online by 11:59 PM ET within 14 days of the conclusion of each activity. Instructions will be provided during the activity.  
  • Upon successful completion of the online form, your statement of completion will be presented to you to print.

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
hsco-hawaii.com
Email Us